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Prostate cancer is the most common non-cutaneous malignancy
diagnosed in men. When it metastasizes, it usually spreads to bone
and/or lymph nodes. A handful of cases have described prostatic
metastases to the lung; however, this is usually in the setting of
existing bone lesions [1]. Herewe describe a unique case inwhich a
patient was found to have both metastatic prostate cancer to
the lung and a primary lung cancer in the absence of any other
evidence of extra-prostatic disease.
2. Case presentation
This is a 60 year-old man who underwent a trans-urethral
resection of his prostate (TURP); pathology returned as
Gleason 4 þ 4 ¼ 8 (Grade group 4). Prostate specific antigen
level (PSA) was 44ng/dL. Bone scan was negative but PET revealed
an FDG-avid lesion in the left lung. This was further evaluated
with a chest CT scan that confirmed a 2cm left upper lobe
lung mass (Fig. 1). He was referred to Thoracic Surgery for
evaluation.
Pulmonary function tests werewithin normal limits however he
had a 40þ pack-year smoking history. He underwent thoracoscopic
resection of the lung mass. Incidentally, there were multiple small
2e3mmnodules present on the surface of the lower lobe. Several of
these were removed with additional wedge resections and frozen
sectioning was positive for malignancy. Given the diffuse disease, a
mediastinal lymph node dissection was performed to ensure
adequate pathologic staging.
On final pathology, the nodule was interpreted as primary
pulmonary adenocarcinoma (Fig. 2). The wedge resections
contained nodules positive for PSA and were interpreted as
metastatic prostatic adenocarcinoma (Fig. 3). The aortopulmonary
lymph node was positive for prostatic adenocarcinoma and
the rest were negative. Given his isolated primary lung cancer
and high likelihood of response to therapy for metastatic
prostate cancer, it was recommended that he undergo completion
left upper lobectomy for treatment of his Stage I primary lung
malignancy.
After completion lobectomy, final Pathology revealed no
additional lung malignancy, but a small 2mm focus of prostate
cancer. He was referred back to his Medical Oncologists and
treated with 6 cycles of docetaxel and Lupron therapy. After
treatment, repeat staging imaging was negative. His PSA following
treatment was 0.7ng/dL. He is planned to continue with Lupron
therapy, and will undergo routine surveillance for his T1bN0 stage
IA lung cancer.
3. Discussion
Metastatic prostate cancer is a relatively common entity and
typically presents with bone metastasis. Metastatic prostate
cancer to the lungs is rare, however. In fact, in the absence of other
metastatic lesions, less than 5 cases have been previously reported
[1e4]. In their case report from 1999, Smith et al. describe a
patient who underwent a radical prostatectomy for Gleason
4 þ 5 ¼ 9 (Grade group 5) disease. When his PSA levels rose,
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Fig. 1. Left lung lesion seen on PET (left) and CT Chest (right).
Fig. 2. (A) Left upper lobe wedge resection of the lung with 2.2 cm nodule of tumor (H&E, original magnification 100); (B) High power image of left upper lobe tumor with lepidic
and acinar growth pattern in the pulmonary parenchyma (H&E, original magnification 200); (C) TTF-1 immunohistochemical stain of pulmonary tumor, consistent with lung
primary (TTF-1, original magnification, 200).
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metastatic work-up revealed a lung nodule. This was removed
by Thoracic Surgery and the pathology returned as metastatic
prostate cancer. The patient's PSA returned to an undetectable
level post-operatively [2].
Hofland and Bagg described a 49 year-old man with
Gleason 4 þ 5 (Grade group 5) cancer who underwent radical
prostatectomy. His PSA increased post-operatively and he under-
went salvage radiation therapy, hormonal therapy, and ultimately
bilateral orchiectomy. PSA after this was undetectable. Two years
later, a chest x-ray revealed a nodule; his PSA was 1.0. The lesion
was removed; pathology was positive for PSA. His PSA continued to
rise after this and ultimately more lesions were found throughout
his skeleton and in his brain. He was lost to follow-up [3]
Two other cases were reported by Kume et al. in the late 1980s.
Both cases were 56 year-old men with biopsy proven prostate
cancer (no Gleason grade given) and lung lesions identified on
staging. One patient underwent bilateral orchiectomy and the other
received hormone therapy; both had complete resolution of their
lung nodules.
In the most recent report, Gago et al. describe three patients
with isolated pulmonary lesions after radical prostatectomy. One
patient's lung lesions were discovered due to biochemical failure.
The other two patients' lung lesions were found for other reasons;
all had elevated PSA levels at the time of detection. One patient
underwent chemotherapy but ultimately died from his disease. The
other twowere treatedwith hormonal therapy; one had a complete
response and the other a partial response [4].
In the setting of a patient with a significant smoking history and a
history of prostatic carcinoma, an FDG avid pulmonary lesion war-
rants biopsy. Differential diagnosis includes metastatic disease, pri-
mary lung cancer, benign, and infectious nodules. Transthoracic
needle aspiration has a sensitivity of 90%, however it has a false
Fig. 3. (A) Wedge resection of the left lung lower lobe revealed a 0.3 cm, well circumscribed tumor nodule (H&E, original magnification 150); (B) The nodule was negative for TTF-
1 and positive for prostate specific antigen (PSA) (PSA immunohistochemical stain, original magnification 150); (C) The nodule displayed similar coalescing glands with round
nuclei and inconspicuous nucleoli, similar to the tumor morphology of the initial prostatic resection, confirming the diagnosis of concomitant metastatic prostatic adenocarcinoma
(H&E, original magnification 200).
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negative rate of up to 22%, and 10e15% risk of pneumothorax [5].
Other diagnostic modalities include EBUS which provides a
diagnostic yield of 56% for peripheral nodules <2 cm in size, and
bronchoscopy which has a success rate of only 34% for peripheral
nodules <2 cm in size [5]. Thoracoscopic wedge resection remains
the gold standard for diagnosis and staging as it affords a valuable
opportunity to evaluate the pleural surfaces, lung parenchyma, nodal
tissue and other structures for potential metastatic disease that is
below the sensitivity of imaging, as was discovered in this case.
4. Conclusion
Metastatic prostate cancer to the lungs remains a rare, albeit not
unheard of, diagnosis. Many of the case reports discussed above
occurred several decades ago and would likely be detected and
managed differently today. Here we present our case of both met-
astatic prostate cancer to the lungs in the absence of other meta-
static sites and a second primary lung malignancy with good early
response. When these cases present, they are best approached by a
multidisciplinary team.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.eucr.2017.11.027.
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